Number of patients, n | 69 |
Follow-up time since inclusion, months (median - IQR) | 15 (6–35) |
Follow-up time since diagnosis, months (median - IQR) | 39 (20.5–108) |
Age at diagnosis, years (median - IQR) | 53 (41.5 – 60) |
Female sex, % (n) | 53.6 (37/69) |
Stage at inclusion, % (n) | |
  Local (AJCC stage I & II) | 46.4 (32/69) |
  Regional (AJCC stage III) | 37.7 (26/69) |
  Systemic (AJCC stage IV) | 15.9 (11/69) |
Active disease at inclusion | 20.3 (14/69) (3 stage III, 11 stage IV) |
Melanoma characteristics | |
  Breslow (median, IQR) | 1.60 (1.08 – 2.60) |
  Ulceration, % (n) | 35.7 (20/56) |
  Sentinel invasion, % (n) | 27.1 (16/59) |
Location of primary melanoma | |
  Head & neck, % (n) | 10.6 (7/69) |
  Trunk, % (n) | 39.4 (26/69) |
  Extremities, % (n) | 50 (33/69) |
  Unknown primary | 3 (3/69) |